## Edgar Filing: Carmine Bryce D. - Form 4

Carmine Bry Form 4											
November 14	ГЛ								OMB AF	PPROVAL	
FORM 4 UNITED STATES SECURITIES A Washington					AND EXCHANGE COMMISSION n, D.C. 20549				OMB Number:	3235-0287	
Subject to Section 16. Form 4 or			F CHANGES IN BENEFICIAL OW SECURITIES Section 16(a) of the Securities Exchang					e Act of 1934,	Expires: Estimated a burden hou response		
may cont See Instru 1(b).	inue. Section 1		of the In	•	•	· ·	•		n		
(Print or Type I	Responses)										
			2. Issuer Name <b>and</b> Ticker or Trading Symbol LILLY ELI & CO [LLY]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Check					x all applicable)			
LILLY CORPORATE CENTER 11/11			(Month/D 11/11/20	-				Director 10% Owner X Officer (give title Other (specify below) below) EVP and Pres, Lilly Bio-Meds			
				Amendment, Date Original d(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
INDIANAF	OLIS, IN 4020	5						Person			
(City)	(State)	(Zip)	Tabl	e I - Non-I	Derivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ion Date 2A. Deemed y/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)				Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	11/11/2011			S <u>(1)</u>	5,700	D	\$ 37.55	57,053	D		
Common Stock								6,755	I	401(k)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Carmine Bryce D. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Amou Unde Secur	le and unt of rlying tities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Carmine Bryce D. LILLY CORPORATE CENTER INDIANAPOLIS, IN 46285			EVP and Pres, Lilly Bio-Meds					
Signatures								
Bronwen Mantlo for Bryce D. Carmin on file	tion	11/14/2011						
<b>**</b> Signature of Reporting Pers	on		Date					

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.